AZ-UNIVERSAL-ELECTRONICS
1.9.2021 22:12:11 CEST | Business Wire | Press release
Universal Electronics Inc. (UEI) (NASDAQ: UEIC), the global leader in wireless universal control solutions for home entertainment and smart home devices, announced that Swiss telecommunications operator Salt , which provides innovative mobile, broadband and TV services, is one of the first providers to offer its voice-enabled Apple TV 4K remote control designed specifically for Multichannel Video Program Distributors (MVPDs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005858/en/
Available since June, Salt customers subscribing to the Salt Home broadband offer will automatically receive UEI’s Apple TV remote control with Apple TV 4K. Salt Home is the most competitive broadband proposition on the Swiss market offering up to 10 gigabits per second symmetric speed over FTTH including a TV service available on Apple TV as a set-top box. Existing customers can also purchase UEI’s Apple TV remote control as a standalone accessory in over 100 Salt stores throughout Switzerland and on Salt’s website .
“UEI has been a strong partner, helping us to provide our customers with a simple and quality remote control designed for Apple TV,” said Pascal Grieder, Salt’s CEO. “The collaboration with UEI across the project has been excellent.”
With Apple TV 4K, subscribers can watch live and on-demand content, as well as use the Apple TV app to watch Apple TV+, buy and rent thousands of movies and TV shows, and enjoy content from other streaming services. Customers can also access Apple Music, Apple Arcade and thousands of other apps, all through this powerful entertainment device built for the biggest screen in the home.
“We enjoyed working with Salt on this project as the Apple TV remote is one of our most exciting new offerings built with the customer in mind,” said Paul Arling, Chairman and CEO of UEI. “We look forward to opportunities to work with them in the future.”
UEI’s Apple TV remote combines Bluetooth Low Energy (BLE) connectivity together with Infrared to provide universal control, and features a range of innovative features and benefits to enhance the TV viewing experience:
- Advanced Search and Control: Customers can ask Siri to find and access content across live TV and streaming apps
- Enhanced Controls for Live TV : Dedicated program guide and channel up/down buttons provide easy and instant access to live TV viewing functions
- Whole Entertainment System Control: Modeless support and universal control of Apple TV, as well as televisions and audio devices from any brand or manufacturer
- Reliable and Secure Communication: Integrated design with UE878, UEI’s reliable and highly integrated BLE chipset optimized for voice control, and Apple’s MFi authentication chip for secure connectivity with Apple TV
- Premium Fit and Feel: Elegant and ergonomic form factor with hard-capped keys on metal domes for enhanced tactile feedback
- Automated Backlit Keys: Accelerometer and ambient light sensor to automatically backlight keys in low light environments when the remote is picked up or moved
About Universal Electronics Inc.
Founded in 1986, Universal Electronics Inc. (NASDAQ: UEIC) is the global leader in wireless universal control solutions for home entertainment and smart home devices. We design, develop, manufacture, ship and support control and sensor technology solutions and a broad line of universal control systems, audio video accessories, and intelligent wireless security and smart home products. Our products and solutions are used by the world's leading brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. For more information, visit www.uei.com .
Apple, Apple TV and Siri are trademarks of Apple Inc. and are not affiliated with UEI. All other trademarks appearing herein are the property of their respective owners.
Safe Harbor Statement
This press release contains forward-looking statements that are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development, delivery and market acceptance of products and technologies identified in this release; the purchasing by Salt and other MVPDs of the products identified in this release in the quantities anticipated by management; the continued penetration and growth of UEI voice recognition technology and other products and consumer technologies identified in this release; and other factors described in UEI’s filings with the Securities and Exchange Commission. The actual results that UEI achieves may differ materially from any forward-looking statement due to such risks and uncertainties. UEI undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005858/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom